RxDoctor Payments Data

Judith Boggess, MD

Internal Medicine · East Ridge, TNNPI 1457315848

Payments from drug & device makers

$1,203in general payments, 2019–2025

Across 42 payments — averaging $28.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Kerecis Limited$324
  • Neurocrine Biosciences, Inc.$153
  • Otsuka America Pharmaceutical, Inc.$110
  • Sunovion Pharmaceuticals Inc.$69
  • Astellas Pharma US Inc$57
  • AstraZeneca$48
  • plus $443 from 16 others

What the payments were for

  • Food & beverage$1,203100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,203 in reported general payments places this provider in the 70th percentile of 2,216 internal medicine providers in Tennessee.

See all internal medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$25,763
Medicare patients
182
Services billed
297

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban506$91,747
AubagioTeriflunomide11$36,563
FarxigaDapagliflozin Propanediol76$19,374
TrulicityDulaglutide23$13,625
XifaxanRifaximin17$12,522
XareltoRivaroxaban80$11,843
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$10,761
SymbicortBudesonide/Formoterol Fumarate40$9,840
JardianceEmpagliflozin62$9,647
MyrbetriqMirabegron63$9,280
TradjentaLinagliptin62$7,968
Breo ElliptaFluticasone/Vilanterol16$7,257
LinzessLinaclotide12$6,740
BrilintaTicagrelor54$6,185
Atorvastatin Calcium1,308$6,008

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Symbicort, Brilinta, Lokelma$48$39,331181 claims
Boehringer IngelheimJardiance, Tradjenta$29$17,615124 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$24$12,52217 claims
Johnson & JohnsonXarelto$30$11,84380 claims
AbbVieLinzess, Restasis$46$10,78224 claims
Astellas Pharma US IncMyrbetriq$57$9,28063 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,216 internal medicine providers in Tennessee.

Other internal medicine in East Ridge

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →